Earnings per share (EPS) is estimated at $1.74, marking a 16% increase year-over-year.
Projected revenue of $728.4 million represents an 11.9% growth from the previous year.
Veeva holds an average brokerage recommendation (ABR) of 1.97, indicating a positive outlook between Strong Buy and Buy.
Veeva Systems Inc. (NYSE:VEEV) is a prominent player in the cloud-based software industry, primarily serving the life sciences sector. The company provides solutions for customer relationship management, content management, and data analytics, helping pharmaceutical and biotechnology companies streamline their operations. Veeva’s competitors include companies like Salesforce and Oracle, which also offer cloud-based solutions across various industries.
As Veeva prepares to release its quarterly earnings on May 28, 2025, analysts have set expectations high with an estimated earnings per share (EPS) of $1.74. This figure represents a 16% increase from the previous year, showcasing the company’s growth trajectory. Revenue is projected to reach $728.4 million, reflecting an 11.9% year-over-year growth. These figures highlight Veeva’s strong market position and its ability to generate substantial revenue.
Wall Street analysts play a significant role in shaping investor sentiment, and their ratings can greatly influence stock prices. Veeva currently holds an average brokerage recommendation (ABR) of 1.97, indicating a position between Strong Buy and Buy. Out of 27 brokerage firms, 14 have given a Strong Buy recommendation, while three have recommended Buy. These ratings account for 51.9% and 11.1% of all recommendations, respectively, suggesting a positive outlook for Veeva.
Despite a slight downward revision of 0.2% in the consensus EPS estimate over the past month, Veeva’s financial metrics remain robust. The company’s price-to-earnings (P/E) ratio is approximately 53, indicating investor confidence in its earnings potential. Veeva’s price-to-sales ratio stands at about 13.82, reflecting the market’s valuation of its revenue. Additionally, the enterprise value to sales ratio is around 13.44, suggesting a strong market valuation relative to sales.
Veeva’s financial health is further underscored by its low debt-to-equity ratio of 0.013, indicating minimal reliance on debt financing. The company also maintains a strong liquidity position with a current ratio of 4.51, highlighting its ability to cover short-term liabilities with short-term assets. These metrics, combined with an earnings yield of about 1.89%, demonstrate Veeva’s solid financial foundation and potential for continued growth.
